XenoPort Reports Encouraging Results of Phase I Parkinson's Trial
Posted on: Thursday, 13 March 2008, 06:00 CDT
XenoPort has announced the positive results from a double-blind, placebo-controlled, single-dose Phase I clinical trial of XP21279, a transported prodrug L-Dopa for the treatment of Parkinson's disease.
The trial compared the pharmacokinetic (PK) profile of L-Dopa (levodopa) produced by a single oral dose of a prototype, sustained-release tablet of XP21279 to that of a near-equivalent single dose of oral L-Dopa. The trial demonstrated that XP21279 produced a more sustained exposure of L-Dopa compared to oral L-Dopa dosed in the same healthy subjects. XP21279 was well-tolerated in this first trial in humans.
Ronald Barrett, XenoPort's CEO, said: "We believe that this clinical trial serves as a solid proof of concept for XP21279. We believe that an optimized formulation of XP21279 could provide therapeutic benefits to patients with Parkinson's disease, particularly in avoiding periods of wearing-off or the return of symptoms that occur during the day with oral L-Dopa therapy."
Source: Datamonitor
Related Articles
- AVANT's Single-Dose Oral Ty800 Vaccine Meets Primary Endpoints in Phase 2 Study
- Single Dose Pandemic Vaccine Effective
- Knopp Neurosciences Presents Results of Phase 1 Ascending Single-Dose Study of KNS-760704
- AVANT Commences Phase 2 Clinical Trial of Its Single Dose, Oral Typhoid Fever Vaccine
- New Cholera Vaccine is Safe and Immunogenic in Infants and Children; AVANT Reports Positive Phase II Study Results of Single Dose Oral CholeraGarde(R)
- Single-Dose Antibiotic Approved
- Pfizer's Single-Dose Antibiotic Zmax(Tm) Receives FDA Approval; Over 36M Prescribed Antibiotics for Sinusitis, Pneumonia in 2004(1)
- Clinical Pharmacokinetics of Lyophilized Recombinant Human Erythropoietin-[Alpha] Following Single-Dose Subcutaneous Administration in Premature Newborns
- The Analgesic Effect of Etoricoxib Relative to That of Two Opioid- Acetaminophen Analgesics: a Randomized, Controlled Single-Dose Study in Acute Dental Impaction Pain*
- Single Dose Phase I Data on CG53135 for the Prevention of Oral Mucositis Presented at ASH
 |
 |
User Comments (0)
RSS Feeds